Survival outcomes of patients with metastatic non-small cell lung cancer receiving chemotherapy or immunotherapy as first-line in a real-life setting

被引：0
作者：
Yaniss Belaroussi
Fanny Bouteiller
Carine Bellera
David Pasquier
Maurice Perol
Didier Debieuvre
Thomas Filleron
Nicolas Girard
Roland Schott
Simone Mathoulin-Pélissier
Anne-Laure Martin
Sophie Cousin
机构：
[1] Univ. Bordeaux,UMR 1219
[2] Bordeaux Population Health Research Center,Inserm CIC1401, Clinical and Epidemiological Research Unit
[3] Epicene Team,Radiotherapy Department
[4] Institut Bergonié,Chest Disease Department
[5] Comprehensive Cancer Center,Medical Oncology Department
[6] Centre Oscar Lambret,Early Phase Trials Unit, Department of Medical Oncology
[7] Medical Oncology Department,undefined
[8] Centre Léon Bérard,undefined
[9] GHRMSA,undefined
[10] Biostatistic and Health Data Science Unit,undefined
[11] Institut Claudius Régaud IUTC-O,undefined
[12] Institut du Thorax Curie-Montsouris,undefined
[13] Medical Oncology Department,undefined
[14] Institut de Cancérologie Strasbourg Europe,undefined
[15] Health Data and Partnership Department,undefined
[16] Unicancer,undefined
[17] Institut Bergonié,undefined
[18] Comprehensive Cancer Center,undefined
来源：
Scientific Reports | / 13卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Treatment of metastatic non-small cell lung cancer (mNSCLC) has been modified due to the development of immunotherapy. We assessed survival outcomes (overall [OS] and progression-free [rwPFS] survivals, time-to-next-treatment [TNT]) in mNSCLC patients after first-line immunotherapy and chemotherapy in real-life settings. Association between rwPFS and TNT, two candidate surrogate endpoints (SE), with OS was assessed. This retrospective multi-center study uses data from patients included in the Epidemio-Strategy Medico-Economic program with mNSCLC over 2015–2019. The impact of treatment on rwPFS/OS was evaluated with Cox models. Individual-level associations between SE and OS were estimated with an iterative multiple imputation approach and joint survival models. The population included 5294 patients (63 years median age). Median OS in immunotherapy group was 16.4 months (95%CI [14.1–NR]) and was higher than in chemotherapy group (11.6 months; 95%CI [11.0–12.2]). Improved OS was observed for the immunotherapy group after 3 months for subjects with performance status 0–1 (HR = 0.59; 95%CI [0.42–0.83], p < 0.01). The associations between rwPFS and TNT with OS were close (τ\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\uptau$$\end{document}=0.57). Results emphasized a survival improvement with immunotherapy for patients in good health condition. There was moderate evidence of individual-level association between candidate SE and OS.
引用
收藏
相关论文
共 189 条
  • [21] Cho BC(2009)Overadjustment bias and unnecessary adjustment in epidemiologic studies Epidemiol. Camb. Mass 20 488-90
  • [22] Turna HZ(2011)An introduction to propensity score methods for reducing the effects of confounding in observational studies Multivar. Behav. Res. 46 399-42
  • [23] Peters S(2016)Variance estimation when using inverse probability of treatment weighting (IPTW) with survival analysis Stat. Med. 35 5642-71
  • [24] Adjei AA(2013)Estimating the correlation of bivariate failure times under censoring Stat. Med. 32 4781-852
  • [25] Gridelli C(2019)One-step validation method for surrogate endpoints using data from multiple randomized cancer clinical trials with failure-time endpoints Stat. Med. 38 2928-56
  • [26] Reck M(2016)The international epidemiology of lung cancer: Latest trends, disparities, and tumor characteristics J. Thorac. Oncol. 11 1653-2316
  • [27] Kerr K(2020)Examining the use of real-world evidence in the regulatory process Clin. Pharmacol. Ther. 107 843-1273
  • [28] Felip E(2019)Real-world outcomes of patients with metastatic non-small cell lung cancer treated with programmed cell death protein 1 inhibitors in the year following U.S. regulatory approval Oncologist 24 648-6
  • [29] West HJ(2020)First-line pembrolizumab for non-small cell lung cancer patients with PD-L1 ≥50% in a multicenter real-life cohort: The PEMBREIZH study Cancer Med. 9 2309-1554
  • [30] Nishio M(2019)Real-world evidence and clinical observations of the treatment of advanced non-small cell lung cancer with PD-1/PD-L1 inhibitors Sci. Rep. 9 4278-21
12345678910